I

Iovance Biotherapeutics, Inc.

478 employees

Iovance Biotherapeutics is developing and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer.

Basic info

Industry

biotechnology research

Sectors

Clinical Trials
Biotechnology
Immuno Oncology
Novel Cancer Immunotherapies
Autologous Cell Therapy
Tumor Infiltrating Lymphocytes (TIL)
Health Diagnostics
Medical
Health Care

Date founded

2007

Funding rounds raised

Total raised

$100M

from 2 investors over 2 rounds

I

Iovance Biotherapeutics, Inc. raised $100M on June 3, 2016

Investors: Frazier Healthcare Partners and OrbiMed Advisors

FAQ